Baricitinib demonstrated its potential as a protective agent against ICIs-related myocarditis by modulating macrophage polarization. These findings provide a solid theoretical foundation for the development of future treatments for ICIs-related myocarditis.

P1, N=24, Recruiting, Fox Chase Cancer Center | Not yet recruiting --> Recruiting

P=N/A, N=93, Completed, AbbVie | Active, not recruiting --> Completed

P2, N=20, Not yet recruiting, University of Zurich

P3, N=90, Recruiting, AbbVie | Trial completion date: Oct 2030 --> Jun 2029

P2, N=74, Terminated, Incyte Corporation | Completed --> Terminated; A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.

P2, N=25, Not yet recruiting, Shanghai Zhongshan Hospital

P3, N=112, Not yet recruiting, AbbVie

P3, N=90, Recruiting, AbbVie | Trial completion date: Jun 2029 --> Oct 2030

P=N/A, N=450, Recruiting, AbbVie | Trial primary completion date: Jun 2026 --> Jul 2027

P3, N=300, Not yet recruiting, AbbVie

P2, N=120, Not yet recruiting, Incyte Corporation

Furthermore, the results from quantitative prediction research suggested that the combination of entrectinib at 600 mg/day with substrates primarily metabolized by hepatic UGT2B15 or intestinal UGT1A7 and UGT1A8 might cause clinical DDIs. Thus, special attention should be paid to avoid adverse reactions induced by DDIs when co-administration of entrectinib and drugs metabolized by UGTs.

In addition, WU derivatives effectively downregulated CXCR3 and T-bet in primary murine T cells. In summary, we have generated novel JAK inhibitors that could serve as alternatives to baricitinib or ruxolitinib.

Later, the patient received fedratinib, a relatively JAK2-selective inhibitor, without relapse of histoplasmosis. Although uncommon, a high index of suspicion for opportunistic IFIs is needed in patients receiving JAK inhibitors. Furthermore, the paucity of data regarding the optimal management of IFIs in patients treated with JAK inhibitors underscore the need for well-designed studies to evaluate the epidemiology, pathobiology, early diagnosis, and multimodal therapy of IFIs in patients with hematological malignancies receiving targeted therapies.

On the other hand, there are some approved drugs, such as pembrolizumab for TMB-H or entrectinib or larotrectinib for NTRK fusion gene, for which there is no stand-alone companion diagnostics and the eligibility for these drugs cannot be judged without the results of CGP test. This paper discusses the current status and issues of companion diagnostics in cancer genomic medicine.

P2, N=0, Withdrawn, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | N=168 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2024 --> Apr 2024

This case report demonstrates the feasibility and role of combination pre-clinical high throughput screening to aid decision making in high-risk leukaemia. It also demonstrates the role a JAK1/2 inhibitor can have in the palliative setting in select patients with AML.

P=N/A, N=1000, Recruiting, AbbVie | Trial completion date: Apr 2024 --> Aug 2025 | Trial primary completion date: Apr 2024 --> Aug 2025

P1/2, N=206, Recruiting, Incyte Corporation | N=100 --> 206 | Trial completion date: Apr 2024 --> Jun 2026 | Trial primary completion date: Apr 2024 --> Nov 2025

P2, N=20, Recruiting, Innovaderm Research Inc. | Not yet recruiting --> Recruiting

P=N/A, N=120, Recruiting, Pfizer | Active, not recruiting --> Recruiting

P1, N=2, Terminated, Joseph Jurcic | N=13 --> 2 | Trial completion date: Dec 2025 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Apr 2024; Closed by Sponsor

Momelotinib-approved for treatment of myelofibrosis in adults with anemia-and its major active metabolite, M21, were assessed as drug-drug interaction (DDI) victims with a strong cytochrome P450 (CYP) 3A4 inhibitor (multiple-dose ritonavir), an organic anion transporting polypeptide (OATP) 1B1/1B3 inhibitor (single-dose rifampin), and a strong CYP3A4 inducer (multiple-dose rifampin). Momelotinib DDI perpetrator potential (multiple-dose) was evaluated with CYP3A4 and breast cancer resistance protein (BCRP) substrates (midazolam and rosuvastatin, respectively)...Safety findings were mild in this short-term study in healthy volunteers. This analysis suggests that momelotinib interactions with OATP1B1/1B3 inhibitors and BCRP substrates may warrant monitoring for adverse reactions or dose adjustments.

Most commonly used agents include hydroxyurea, interferon, Janus kinase inhibitors, and hypomethylating agents, though none are disease-modifying. Actionable mutations (NRAS/KRAS, ETNK1) have also been identified, supporting novel agents targeting involved pathways. Preclinical and clinical studies evaluating new drugs (e.g., fedratinib, phase 2) and combinations are detailed.

For patients with multiple myeloma, treatment with RUX and MP is effective and well tolerated, and LEN can be used to extend the benefit of this RUX-based treatment.

P3, N=100, Completed, Pfizer | Active, not recruiting --> Completed

P3, N=329, Completed, Incyte Corporation | Active, not recruiting --> Completed

P=N/A, N=137, Recruiting, Bristol-Myers Squibb | Trial completion date: Sep 2029 --> Dec 2027

P2, N=23, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2024 --> Aug 2024

The follow-up CT scan revealed peritoneal nodules suggestive of peritoneal dissemination, and Entrectinib (a TRK inhibitor) was administered...The present case may offer new insights into the potential introduction of TRK inhibitors as treatments for GISTs with NTRK fusions. Additionally, the presence of abundant lymphoid infiltration in the present case may prompt further research into immunotherapy as a possible additional therapeutic option.

Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. Due to its mechanism of action, MMB represents a valuable therapeutic option in MF, addressing the clinical challenge of anemia and potentially improving outcomes for patients with hematologic malignancies. Ongoing research explores MMB's potential in acute myeloid leukemia and combination therapies.

The 5-year benefit-risk profile for upadacitinib in RA remains favorable.

P1/2, N=47, Recruiting, Ohio State University Comprehensive Cancer Center | Suspended --> Recruiting

Drug synergy was seen using trametinib and rapamycin in combination with entrectinib.

These newer agents add novel mechanisms of action to the expanding therapeutic armamentarium of advanced therapies to treat ulcerative colitis. Based on expert opinion and available data to date, we propose a practical guide on positioning of these new agents for the treatment of ulcerative colitis. In mild-to-moderate disease, one should consider using ozanimod or etrasimod as first-line agents. In moderate-to-severe disease, we favor using mirizikizumab as first-line agent. In patients who have failed an anti-tumor necrosis factor agent, upadacitinib or mirizikizumab should be considered using patient factors and safety to guide one's decision between these two agents.

P3, N=1500, Enrolling by invitation, AbbVie | Active, not recruiting --> Enrolling by invitation | N=968 --> 1500

P=N/A, N=7807, Completed, Pfizer | N=4012 --> 7807

P1, N=60, Active, not recruiting, Case Comprehensive Cancer Center | Trial primary completion date: Dec 2023 --> Jun 2024

P2, N=24, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed

P2, N=186, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting

P3, N=225, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting